Literature DB >> 15455411

FDA/PI flow cytometry assay of complement-mediated cytotoxicity of antibodies generated during xenotransplantation.

Tomas M Díaz1, Sonia Pértega, Dolores Ortega, Eduardo López, Alberto Centeno, Rafael Mañez, Nieves Doménech.   

Abstract

BACKGROUND: A flow cytometry complement-mediated cytotoxicity assay (FCCA) using fluorescein diacetate (FDA) and propidium iodide (PI) to measure antibody-dependent toxicity is useful to determine the success of xenotransplant organs. We evaluated the validity of different mathematical models as a measure of cytotoxicity in FCCA.
METHODS: Sera from untreated baboons (n = 7) and from immunosuppressed animals (n = 5) undergoing different xenotransplantation protocols with pig organs were tested by endogenous FCCA and a similar assay also using exogenous complement, and the results were compared with those of a complement-dependent hemolytic assay to detect anti-pig antibodies (APHA). The influence of PI/FDA staining and the use of several mathematical models were analyzed.
RESULTS: For both groups of animals, we observed high correlations between the endogenous and exogenous FCCA pathways and between calculations based on PI and FDA staining. Of the four mathematical models tested--the Von Krogh equation, two exponential models, and area under the curve--the Von Krogh equation was the most appropriate in terms of goodness of fit and concordance with APHA.
CONCLUSIONS: FDA/PI FCCA is useful to measure endogenous and exogenous complement-mediated cytotoxicities, and it has advantages related to identification of potential new xenoantibodies. Although all four mathematical models produced acceptable solutions, the Von Krogh equation was the best option. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455411     DOI: 10.1002/cyto.a.20076

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  4 in total

1.  Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall.

Authors:  Shengwen Calvin Li; Long T Vu; Hector W Ho; Hong Zhen Yin; Vic Keschrumrus; Qiang Lu; Jun Wang; Heying Zhang; Zhiwei Ma; Alexander Stover; John H Weiss; Philip H Schwartz; William G Loudon
Journal:  Cancer Cell Int       Date:  2012-09-20       Impact factor: 5.722

2.  Examining the Biosynthesis and Xenoantigenicity of Class II Swine Leukocyte Antigen Proteins.

Authors:  Joseph M Ladowski; Gregory R Martens; Luz M Reyes; Zheng-Yu Wang; Devin E Eckhoff; Vera Hauptfeld-Dolejsek; Matt Tector; A Joseph Tector
Journal:  J Immunol       Date:  2018-03-14       Impact factor: 5.422

3.  Mesenchymal stem cells engineered to inhibit complement-mediated damage.

Authors:  Melisa A Soland; Mariana Bego; Evan Colletti; Esmail D Zanjani; Stephen St Jeor; Christopher D Porada; Graça Almeida-Porada
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

4.  Comparative Analysis of the Different Dyes' Potential to Assess Human Normal and Cancer Cell Viability In Vitro under Different D/H Ratios in a Culture Medium.

Authors:  I A Zlatskiy; A V Zlatska; N V Antipova; S A Dolenko; I M Gordiienko; O S Gubar; R G Vasyliev; D A Zubov; S N Novikova; A V Syroeshkin
Journal:  ScientificWorldJournal       Date:  2020-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.